MEP47208A - 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors - Google Patents

4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors

Info

Publication number
MEP47208A
MEP47208A MEP-472/08A MEP47208A MEP47208A ME P47208 A MEP47208 A ME P47208A ME P47208 A MEP47208 A ME P47208A ME P47208 A MEP47208 A ME P47208A
Authority
ME
Montenegro
Prior art keywords
quinazolines
quinolines
phenylamino
tyrosine kinase
kinase inhibitors
Prior art date
Application number
MEP-472/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Frank Himmelsbach
Birgit Jung
Flavio Solca
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10214412A external-priority patent/DE10214412A1/de
Priority claimed from DE2002131711 external-priority patent/DE10231711A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP47208A publication Critical patent/MEP47208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-472/08A 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors MEP47208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10214412A DE10214412A1 (de) 2002-03-30 2002-03-30 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE2002131711 DE10231711A1 (de) 2002-07-13 2002-07-13 Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PCT/EP2003/003062 WO2003082290A1 (fr) 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines / quinolines en tant qu'inhibiteurs de la tyrosine kinase

Publications (1)

Publication Number Publication Date
MEP47208A true MEP47208A (en) 2011-02-10

Family

ID=28676040

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-472/08A MEP47208A (en) 2002-03-30 2003-03-25 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1492536B1 (fr)
JP (1) JP4776882B2 (fr)
KR (1) KR101064530B1 (fr)
CN (1) CN1642552B (fr)
AR (1) AR039187A1 (fr)
AT (1) ATE557008T1 (fr)
AU (1) AU2003226705B2 (fr)
BR (1) BR0308902A (fr)
CA (1) CA2476008C (fr)
EA (2) EA009300B1 (fr)
HK (1) HK1079095A1 (fr)
HR (1) HRP20040898A2 (fr)
IL (1) IL164167A0 (fr)
ME (1) MEP47208A (fr)
MX (1) MXPA04009536A (fr)
MY (1) MY127771A (fr)
NO (1) NO329271B1 (fr)
NZ (1) NZ536114A (fr)
PE (1) PE20040169A1 (fr)
PL (1) PL371188A1 (fr)
RS (1) RS85404A (fr)
TW (2) TW201024269A (fr)
UY (1) UY27737A1 (fr)
WO (1) WO2003082290A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1731511B1 (fr) 1999-06-21 2015-08-12 Boehringer Ingelheim Pharma GmbH & Co. KG Heterocycles bicycliques, medicaments contenant ces composés, leur utilisation et procédés permettant de les préparer
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
JP4703183B2 (ja) * 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
EP1636195A1 (fr) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines et pyrido 3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
MXPA06001079A (es) * 2003-07-29 2006-04-11 Astrazeneca Ab Derivados de piperidil quinazolina como inhibidores de cinasa de tirosina.
SI1667991T1 (sl) * 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
EP1664028A1 (fr) * 2003-09-16 2006-06-07 AstraZeneca AB Dérivés de quinozaline en tant qu'inhibiteurs de la tyrosine kinase
ATE352550T1 (de) * 2003-09-19 2007-02-15 Astrazeneca Ab Chinazolinderivate
EP1670782B1 (fr) * 2003-09-19 2007-02-14 AstraZeneca AB Derives de quinazoline
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10345875A1 (de) * 2003-09-30 2005-04-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Vewendung und Verfahren zu ihrer Herstellung
DE10350717A1 (de) * 2003-10-30 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN1893944B (zh) 2003-12-18 2011-07-06 詹森药业有限公司 具有抗增殖活性的3-氰基喹啉衍生物
WO2005058913A1 (fr) 2003-12-18 2005-06-30 Janssen Pharmaceutica N.V. Anti-proliferants a base de derives pyrido- et pyrimidopyrimidine
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
ATE501148T1 (de) 2004-12-14 2011-03-15 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1833482A4 (fr) 2005-01-03 2011-02-16 Myriad Genetics Inc Composés bicycliques azotés et utilisation thérapeutique associée
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
EA200701619A1 (ru) * 2005-02-04 2008-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Применение ингибиторов тирозинкиназы для лечения хронического риносинусита
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
MX2007010399A (es) * 2005-02-26 2007-09-25 Astrazeneca Ab Derivados de quinazolina en la forma de inhibidores de cinasa de tirosina.
WO2007023073A2 (fr) * 2005-08-22 2007-03-01 Boehringer Ingelheim International Gmbh Heterocycles bicycliques, produits pharmaceutiques contenant ces composes, leur utilisation et procede pour les preparer
ATE488513T1 (de) 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
WO2007054550A1 (fr) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Derives de quinazoline pour le traitement des affections cancereuses
AU2006326157A1 (en) * 2005-12-12 2007-06-21 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof
EP1996561A1 (fr) * 2006-03-09 2008-12-03 Boehringer Ingelheim International GmbH Heterocycles bicycliques, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
AU2007274284B2 (en) 2006-07-13 2012-04-26 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
JP2010502743A (ja) * 2006-09-11 2010-01-28 キュリス，インコーポレイテッド 抗増殖薬剤としての多機能性低分子
MX2009002585A (es) * 2006-09-11 2009-08-24 Curis Inc Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
EP1921070A1 (fr) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
EP2118075A1 (fr) * 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Hétérocycles bicycliques, agents pharmaceutiques contenant ces composés, leur utilisation et leur procédé de préparation
EP1956010A1 (fr) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Hétérocycles bicycliques, médicament contenant cette composition, son utilisation et son procédé de fabrication
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
RS52573B (en) * 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh SPIROCYCLIC HETEROCYCLES, THE MEDICINAL PRODUCTS CONTAINING THIS UNIT, THEIR APPLICATION AND THE PROCEDURE FOR THEIR MANUFACTURING
NZ589883A (en) * 2008-05-13 2012-06-29 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
US8263768B2 (en) * 2008-08-08 2012-09-11 Boehringer Ingelheim International Gmbh Process for the stereoselective preparation of bicyclic heterocycles
US8372855B2 (en) 2008-08-08 2013-02-12 Boehringer Ingelheim International Gmbh Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof
EP2313397B1 (fr) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Hétérocycles substitués par cyclohexyloxy, médicament contenant ces liaisons, leur utilisation et leur procédé de fabrication
CN101659657B (zh) * 2008-08-29 2014-05-14 北大方正集团有限公司 氰基取代的喹啉衍生物及其制备方法和用途
CN101659658B (zh) * 2008-08-29 2014-04-02 北大方正集团有限公司 氰基取代的喹啉衍生物
EP2346507A1 (fr) * 2008-09-03 2011-07-27 Boehringer Ingelheim International GmbH Utilisation de dérivés de quinazoline pour le traitement de maladies virales
SI2451445T1 (sl) 2009-07-06 2019-07-31 Boehringer Ingelheim International Gmbh Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino
CN102030742B (zh) 2009-09-28 2013-06-19 齐鲁制药有限公司 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
AR080176A1 (es) * 2010-02-15 2012-03-21 Boehringer Ingelheim Int Sales e hidratos de la 4-((3-cloro-4-fluoro-fenil)amino)-6-(cis-4-(n-((morf-1-olin-4-il)carbonil)-n-metil-amino)-ciclohexan-1-iloxi)-7-metoxi-quinazolina, su uso como medicamento y su preparacion
CN102452988B (zh) * 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
MX2013008870A (es) * 2011-02-01 2013-08-14 Boehringer Ingelheim Int Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazoli n-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion.
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
AU2013218119A1 (en) 2012-02-09 2014-07-17 Boehringer Ingelheim International Gmbh Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro [5.5] undecanes
EP2752413B1 (fr) 2012-03-26 2016-03-23 Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences Dérivé de quinazoline et son application
EP2875020B1 (fr) 2012-07-19 2017-09-06 Boehringer Ingelheim International GmbH Procédé de pràparation de une sel d'acide fumarique de la 9-[4-(3-chloro-2-fluoro-phénylamino)-7-méthoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undécan-5-one
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CA2901269C (fr) * 2013-03-06 2022-01-18 Astrazeneca Ab Inhibiteurs quinazoline de l'activation des formes mutantes du recepteur de croissance epidermique (egfr)
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
TWI771327B (zh) * 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
JP2022529518A (ja) 2019-04-25 2022-06-22 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム チロシンキナーゼの複素環式阻害剤
AR120406A1 (es) 2019-11-06 2022-02-09 Yuhan Corp Compuestos de pirrolidina y piperidina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
DE10042059A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
CN1642552A (zh) 2005-07-20
KR101064530B1 (ko) 2011-09-14
ATE557008T1 (de) 2012-05-15
CA2476008C (fr) 2011-12-13
KR20040094898A (ko) 2004-11-10
AR039187A1 (es) 2005-02-09
NZ536114A (en) 2007-11-30
MXPA04009536A (es) 2005-01-25
TW201024269A (en) 2010-07-01
UY27737A1 (es) 2003-10-31
BR0308902A (pt) 2005-01-04
EA200701302A1 (ru) 2007-12-28
AU2003226705B2 (en) 2008-11-06
NO20043997L (no) 2004-10-27
TWI331604B (en) 2010-10-11
EP1492536A1 (fr) 2005-01-05
TW200406211A (en) 2004-05-01
MY127771A (en) 2006-12-29
JP4776882B2 (ja) 2011-09-21
AU2003226705A1 (en) 2003-10-13
RS85404A (en) 2007-02-05
CN1642552B (zh) 2010-05-12
PE20040169A1 (es) 2004-05-24
JP2005529090A (ja) 2005-09-29
CA2476008A1 (fr) 2003-10-09
EA200401191A1 (ru) 2005-04-28
NO329271B1 (no) 2010-09-20
IL164167A0 (en) 2005-12-18
EP1492536B1 (fr) 2012-05-09
PL371188A1 (en) 2005-06-13
EA009300B1 (ru) 2007-12-28
WO2003082290A1 (fr) 2003-10-09
HK1079095A1 (en) 2006-03-31
HRP20040898A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
MEP47208A (en) 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
MEP59508A (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
MEP58708A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
YU65801A (sh) Biciklična heterociklična jedinjenja, farmaceutske kompozicije koje sadrže ova jedinjenja i postupci za njihovo pripremanje
MEP45508A (en) Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
TW200730508A (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
TW200505912A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
TR200102505T2 (tr) 4-amino-kinazolin ve kinolin türevleri.
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO971038D0 (no) Pyrimido£5,4-D|pyrimidiner, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for fremstilling av dem
MY150290A (en) Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
UY26902A1 (es) Heterocíclicos bicíclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparación
TW200510341A (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE386530T1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
ATE412632T1 (de) Neue aryl-haltige 5-acylindolinone, deren herstellung und deren verwendung als arzneimittel
MX2009007610A (es) Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
ATE305787T1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE321572T1 (de) Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren
YU60501A (sh) Derivati 4-amino-hinazolina i hinolina koji imaju inhibitorno dejstvo na prenos signala posredovanog tirozin kinazom